|
1
|
Effiom OA, Adeyemo WL, Omitola OG, Ajayi
OF, Emmanuel MM and Gbotolorun OM: Oral squamous cell carcinoma: a
clinicopathologic review of 233 cases in Lagos, Nigeria. J Oral
Maxillofac Surg. 66:1595–1599. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zushi Y, Narisawa-Saito M, Noguchi K,
Yoshimatsu Y, Yugawa T, Egawa N, Fujita M, Urade M and Kiyono T: An
in vitro multistep carcinogenesis model for both HPV-positive and
-negative human oral squamous cell carcinomas. Am J Cancer Res.
1:869–881. 2011.PubMed/NCBI
|
|
3
|
Weng CJ, Hsieh YH, Chen MK, Tsai CM, Lin
CW and Yang SF: Survivin SNP-carcinogen interactions in oral
cancer. J Dent Res. 91:358–363. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mascolo M, Siano M, Ilardi G, Russo D,
Merolla F, De Rosa G and Staibano S: Epigenetic disregulation in
oral cancer. Int J Mol Sci. 13:2331–2353. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mydlarz WK, Hennessey PT and Califano JA:
Advances and perspectives in the molecular diagnosis of head and
neck cancer. Expert Opin Med Diagn. 4:53–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen YJ, Chang JT, Liao CT, Wang HM, Yen
TC, Chiu CC, Lu YC, Li HF and Cheng AJ: Head and neck cancer in the
betel quid chewing area: recent advances in molecular
carcinogenesis. Cancer Sci. 99:1507–1514. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Agrawal D, Gupta S, Agarwal D, Gupta OP
and Agarwal M: Role of GSTM1 and GSTT1 polymorphism: susceptibility
to oral submucous fibrosis in the North Indian population.
Oncology. 79:181–186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marks PA and Dokmanovic M: Histone
deacetylase inhibitors: discovery and development as anticancer
agents. Expert Opin Investig Drugs. 14:1497–1511. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Delcuve GP, Khan DH and Davie JR:
Targeting class I histone deacetylases in cancer therapy. Expert
Opin Ther Targets. 17:29–41. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lucio-Eterovic AK, Cortez MA, Valera ET,
Motta FJ, Queiroz RG, Machado HR, et al: Differential expression of
12 histone deacetylase (HDAC) genes in astrocytomas and normal
brain tissue: class II and IV are hypoexpressed in glioblastomas.
BMC Cancer. 8:243–253. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Martin M, Kettmann R and Dequiedt F: Class
IIa histone deacetylases: regulating the regulators. Oncogene.
26:5450–5467. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Weichert W, Denkert C, Noske A,
Darb-Esfahani S, Dietel M, Kalloger SE, Huntsman DG and Köbel M:
Expression of Class I histone deacetylases indicates poor prognosis
in endometrioid subtypes of ovarian and endometrial carcinomas.
Neoplasia. 10:1021–1027. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Iglesias-Linares A, Yañez-Vico RM and
González-Moles MA: Potential role of HDAC inhibitors in cancer
therapy: insights into oral squamous cell carcinoma. Oral Oncol.
46:323–329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chang HH, Chiang CP, Hung HC, Lin CY, Deng
YT and Kuo MY: Histone deacetylase 2 expression predicts poorer
prognosis in oral cancer patients. Oral Oncol. 45:610–614. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oehme I, Deubzer HE, Wegener D, Pickert D,
Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von
Deimling A, et al: Histone deacetylase 8 in neuroblastoma
tumorigenesis. Clin Cancer Res. 15:91–99. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim SA, Kwon SM, Yoon JH and Ahn SG: The
antitumor effect of PLK1 and HSF1 double knockdown on human oral
carcinoma cells. Int J Oncol. 36:867–872. 2010.PubMed/NCBI
|
|
18
|
Kanematsu S, Uehara N, Miki H, Yoshizawa
K, Kawanaka A, Yuri T and Tsubura A: Autophagy inhibition enhances
sulforaphane-induced apoptosis in human breast cancer cells.
Anticancer Res. 30:3381–3390. 2010.PubMed/NCBI
|
|
19
|
Shakespear MR, Halili MA, Irvine KM,
Fairlie DP and Sweet MJ: Histone deacetylases as regulators of
inflammation and immunity. Trends Immunol. 32:335–343. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lehmann M, Hoffmann MJ, Koch A, Ulrich SM,
Schulz WA and Niegisch G: Histone deacetylase 8 is deregulated in
urothelial cancer but not a target for efficient treatment. J Exp
Clin Cancer Res. 10:592014. View Article : Google Scholar
|
|
21
|
Lopez G, Bill KL, Bid HK, Braggio D,
Constantino D, Prudner B, Zewdu A, Batte K, Lev D and Pollock RE:
HDAC8, a potential therapeutic target for the treatment of
malignant peripheral nerve sheath tumors (MPNST). PLoS One.
10:e01333022015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nakagawa M, Oda Y, Eguchi T, Aishima S,
Yao T, Hosoi F, Basaki Y, Ono M, Kuwano M, Tanaka M, et al:
Expression profile of class I histone deacetylases in human cancer
tissues. Oncol Rep. 18:769–774. 2007.PubMed/NCBI
|
|
23
|
Niegisch G, Knievel J, Koch A, Hader C,
Fischer U, Albers P and Schulz WA: Changes in histone deacetylase
(HDAC) expression patterns and activity of HDAC inhibitors in
urothelial cancers. Urol Oncol. 31:1770–1779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim HJ and Bae SC: Histone deacetylase
inhibitors: molecular mechanisms of action and clinical trials as
anti-cancer drugs. Am J Transl Res. 3:166–179. 2011.PubMed/NCBI
|
|
25
|
Gray SG and Ekstrom TJ: The human histone
deacetylase family. Exp Cell Res. 262:75–83. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
de Ruijter AJ, van Gennip AH, Caron HN,
Kemp S and van Kuilenburg AB: Histone deacetylases (HDACs):
characterization of the classical HDAC family. Biochem J.
370:737–749. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gregoretti IV, Lee YM and Goodson HV:
Molecular evolution of the histone deacetylase family: functional
implications of phylogenetic analysis. J Mol Biol. 338:17–31. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Oehme I, Deubzer HE, Lodrini M, Milde T
and Witt O: Targeting of HDAC8 and investigational inhibitors in
neuroblastoma. Expert Opin Investig Drugs. 18:1605–1617. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Waltregny D, De Leval L, Glénisson W, Ly
Tran S, North BJ, Bellahcène A, Weidle U, Verdin E and Castronovo
V: Expression of histone deacetylase 8, a class I histone
deacetylase, is restricted to cells showing smooth muscle
differentiation in normal human tissues. Am J Pathol. 165:553–564.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Waltregny D, North B, Van Mellaert F, de
Leval J, Verdin E and Castronovo V: Screening of histone
deacetylases (HDAC) expression in human prostate cancer reveals
distinct class I HDAC profiles between epithelial and stromal
cells. Eur J Histochem. 48:273–290. 2004.PubMed/NCBI
|
|
31
|
Mathias RA, Guise AJ and Cristea IM:
Post-translational modifications regulate class IIa histone
deacetylase (HDAC) function in health and disease. Mol Cell
Proteomics. 14:456–470. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Quan P, Moinfar F, Kufferath I, Absenger
M, Kueznik T, Denk H, Zatloukal K and Haybaeck J: Effects of
targeting endometrial stromal sarcoma cells via histone deacetylase
and PI3K/AKT/mTOR signaling. Anticancer Res. 34:2883–2897.
2014.PubMed/NCBI
|
|
33
|
Wu J, Du C, Lv Z, Ding C, Cheng J, Xie H,
Zhou L and Zheng S: The up-regulation of histone deacetylase 8
promotes proliferation and inhibits apoptosis in hepatocellular
carcinoma. Dig Dis Sci. 58:3545–3553. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu JJ, Lin M, Yu JY, Liu B and Bao JK:
Targeting apoptotic and autophagic pathways for cancer
therapeutics. Cancer Lett. 300:105–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hannigan AM and Gorski SM: Macroautophagy:
the key ingredient to a healthy diet? Autophagy. 5:140–151. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Q, Yang W, Man N, Zheng F, Shen Y,
Sun K, Li Y and Wen LP: Autophagy-mediated chemosensitization in
cancer cells by fullerene C60 nanocrystal. Autophagy. 5:1107–1117.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Levine B: Cell biology: Autophagy and
cancer. Nature. 446:745–747. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kondo Y, Kanzawa T, Sawaya R and Kondo S:
The role of autophagy in cancer development and response to
therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jin SK and White E: Tumor suppression by
autophagy through the management of metabolic stress. Autophagy.
4:563–566. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee JY and Yao TP: Quality control
autophagy: a joint effort of ubiquitin, protein deacetylase and
actin cytoskeleton. Autophagy. 6:555–557. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Park JY and Juhnn YS: cAMP signaling
increases histone deacetylase 8 expression by inhibiting
JNK-dependent degradation via autophagy and the proteasome system
in H1299 lung cancer cells. Biochem Biophys Res Commun.
470:336–342. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ahn MY, Ahn SG and Yoon JH: Apicidin, a
histone deaceylase inhibitor, induces both apoptosis and autophagy
in human oral squamous carcinoma cells. Oral Oncol. 47:1032–1038.
2011. View Article : Google Scholar : PubMed/NCBI
|
